AbbVie Inc.
ABBV
Κατάταξη σε μετοχές
#25
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Τιμή μετοχής
$285.11
Τελευταίος συγχρονισμός: 2026-10-16
Κεφαλαιοποίηση
$503.82B
Αλλαγή (1 ημέρα)
0.78%
Αλλαγή (1 έτος)
24.37%
Χώρα
US
Εμπόριο AbbVie Inc. (ABBV)
Κατηγορία
Healthcare
EPS για AbbVie Inc. (ABBV)
EPS στις December 2025 TTM: $2.37
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της AbbVie Inc., το τρέχον EPS της εταιρείας (TTM) είναι $2.37. Στο τέλος του 2026, η εταιρεία είχε EPS 0, ίσο με το EPS του 2026 που ήταν 0.
Ιστορικό EPS της AbbVie Inc. από 2026 έως 2026
EPS στο τέλος κάθε έτους
| Έτος | EPS | Αλλαγή |
|---|---|---|
| Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες. | ||
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | EPS | Διαφορά EPS | Χώρα |
|---|---|---|---|
| $29.89 | 1,161.18% |
US
|
|
| $6.60 | 178.48% |
US
|
|
| $20.39 | 760.30% |
CH
|
|
| $1.26 | -46.84% |
US
|
|
| $7.19 | 203.38% |
CH
|
